VivoSim Labs, Inc.

VIVS Healthcare Biotechnology

VivoSim Labs, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $131,000.00, down 9.03% from fiscal 2025. In the quarter to June 2026, revenue fell 51.4%, EPS grew 78.1% and free cash flow grew 17.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.16 0.01 −5.88%
Market cap
$2.8M
P/E
0.0×
Fwd P/E
−0.2×
Dividend yield
—
F-score
3/9
Altman Z
−71.71
Beneish M
29.46
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

— 5 3 4
ROE
(36.91%) (51.07%) (294.75%) (343.10%)
ROA
(24.12%) (22.71%) (125.64%) (155.93%)
ROIC
(1,960.70%) (4,678.92%) 0.00% 0.00%
Return on Tangible Assets
(36.44%) (32.17%) (341.97%) (810.64%)
Average Days of Receivables
83.43 2,683.52 2,914.43 3,405.58
Free Cash Flow per Share
(3.90) (4.07) (4.18) (0.22)
Free Cash Flow
(10.15) (10.62) (10.83) (1.14)
Other line items

Show all line items

Columns are period end dates